Thomas Zeyen

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial

Frank A. Giordano, Julian Philipp Layer, Sonia Leonardelli et al. · Nature Communications · 2024 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17

Microglial-specific depletion of TAK1 is neuroprotective in the acute phase after ischemic stroke

Thomas Zeyen, Rozina Noristani, Shahin Habib et al. · Journal of Molecular Medicine · 2020 · 49 citations · Full text

Life Sciences, Neurology, Neuroscience +16

Erythropoietin Abrogates Post-Ischemic Activation of the NLRP3, NLRC4, and AIM2 Inflammasomes in Microglia/Macrophages in a TAK1-Dependent Manner

Ole Heinisch, Thomas Zeyen, Tobias Goldmann et al. · Translational Stroke Research · 2021 · 37 citations · Full text

Life Sciences, Immunology, Neuroscience +17

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

Thomas Zeyen, Anna‐Laura Potthoff, Robert Németh et al. · Trials · 2022 · 32 citations · Full text

Medicine, Oncology, Pharmacology +15

Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain‐derived neurotrophic factor

Daniel Komnig, Toruntay Cem Dagli, Pardes Habib et al. · Journal of Neurochemistry · 2018 · 26 citations · Full text

Life Sciences, Neurology, Pharmacology +17